Nasser Gholijani1, Marjan Gharagozloo2, Fathollah Kalantar3, Amin Ramezani4, Zahra Amirghofran5. 1. Autoimmune Diseases Research Center, Shiraz University of Medical Sciences, Shiraz, Iran. 2. Department of Immunology, Isfahan University of Medical Sciences, Isfahan, Iran. ; Department of Pediatrics, CR-CHUS, Faculty of Medicine and Health Sciences, University of Sherbrooke, Sherbrooke,Quebec,Canada. 3. Department of Immunology, Shiraz University of Medical Sciences, Shiraz, Iran. 4. Department of Medical Biotechnology, School of Advanced Medical Sciences and Technology, Shiraz University of Medical Sciences, Shiraz, Iran. ; Institute for Cancer Research, Shiraz University of Medical sciences, Shiraz, Iran. 5. Department of Immunology, Shiraz University of Medical Sciences, Shiraz, Iran. ; Medicinal and Natural Products Chemistry Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Abstract
PURPOSE: Thymol and carvacrol, two main components of thyme, have shown anti-inflammatory effects. The aim of this study was to assess the effects of these components on Jurkat leukemia cells as an in vitro T cell model and their molecular mechanisms of activity. METHODS: Cells were cultured in the presence of components and subsequently stimulated with phorbol-12-myristate-13-acetate (PMA)/calcium ionophore for evaluating interleukin (IL)-2 and interferon (IFN)-γ production. The activation of T cell transcription factors that included nuclear factors of activated T cells (NFATs), activator protein-1 (AP-1; c-Jun/c-Fos), and nuclear factor (NF)-κB were examined by Western blot analysis. RESULTS: Thymol and carvacrol at 25 µg/ml significantly reduced IL-2 levels from 119.4 ± 8pg/ml in control cells treated only with PMA/Calcium ionophore and the solvent to 66.9 ± 6.4pg/ml (thymol) and 32.3 ± 3.6pg/ml (carvacrol) and IFN-γ from 423.7 ± 19.7pg/ml in control cells to 311.9 ± 11.6pg/ml (thymol) and 293.5 ± 16.7pg/ml (carvacrol). Western blot analyses of nuclear extracts showed that the same concentrations of components significantly reduced NFAT-2 to 44.2 ± 2.7% (thymol) and 91.4 ± 2.3% (carvacrol) of the control (p<0.05), and c-Fos to 31.2 ± 6.2% (thymol) and 27.6 ± 3.1% (carvacrol) of the control (p<0.01). No effects on NFAT-1, c-Jun and phospho-NF-κBp65 levels were observed. CONCLUSION: Thymol and carvacrol could contribute to modulation of T cell activity by reducing IL-2 and IFN-γ production possibly through down regulation of AP-1 and NFAT-2 transcription factors suggesting their potential usefulness for reduction of T cell overactivity in immune-mediated diseases.
PURPOSE: Thymol and carvacrol, two main components of thyme, have shown anti-inflammatory effects. The aim of this study was to assess the effects of these components on Jurkat leukemia cells as an in vitro T cell model and their molecular mechanisms of activity. METHODS: Cells were cultured in the presence of components and subsequently stimulated with phorbol-12-myristate-13-acetate (PMA)/calcium ionophore for evaluating interleukin (IL)-2 and interferon (IFN)-γ production. The activation of T cell transcription factors that included nuclear factors of activated T cells (NFATs), activator protein-1 (AP-1; c-Jun/c-Fos), and nuclear factor (NF)-κB were examined by Western blot analysis. RESULTS: Thymol and carvacrol at 25 µg/ml significantly reduced IL-2 levels from 119.4 ± 8pg/ml in control cells treated only with PMA/Calcium ionophore and the solvent to 66.9 ± 6.4pg/ml (thymol) and 32.3 ± 3.6pg/ml (carvacrol) and IFN-γ from 423.7 ± 19.7pg/ml in control cells to 311.9 ± 11.6pg/ml (thymol) and 293.5 ± 16.7pg/ml (carvacrol). Western blot analyses of nuclear extracts showed that the same concentrations of components significantly reduced NFAT-2 to 44.2 ± 2.7% (thymol) and 91.4 ± 2.3% (carvacrol) of the control (p<0.05), and c-Fos to 31.2 ± 6.2% (thymol) and 27.6 ± 3.1% (carvacrol) of the control (p<0.01). No effects on NFAT-1, c-Jun and phospho-NF-κBp65 levels were observed. CONCLUSION: Thymol and carvacrol could contribute to modulation of T cell activity by reducing IL-2 and IFN-γ production possibly through down regulation of AP-1 and NFAT-2 transcription factors suggesting their potential usefulness for reduction of T cell overactivity in immune-mediated diseases.
Authors: Adriana G Guimarães; Maria A Xavier; Marília T de Santana; Enilton A Camargo; Cliomar A Santos; Fabíola A Brito; Emiliano O Barreto; Sócrates C H Cavalcanti; Angelo R Antoniolli; Rita C M Oliveira; Lucindo J Quintans-Júnior Journal: Naunyn Schmiedebergs Arch Pharmacol Date: 2011-12-03 Impact factor: 3.000
Authors: Mahmoud M Bendary; Doaa Ibrahim; Rasha A Mosbah; Farag Mosallam; Wael A H Hegazy; Naglaa F S Awad; Walaa A Alshareef; Suliman Y Alomar; Sawsan A Zaitone; Marwa I Abd El-Hamid Journal: Antibiotics (Basel) Date: 2020-12-30
Authors: Sareh Kamran; Ajantha Sinniah; Mahfoudh A M Abdulghani; Mohammed Abdullah Alshawsh Journal: Cancers (Basel) Date: 2022-02-22 Impact factor: 6.639